Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Arch Pathol Lab Med ; 145(12): 1499-1504, 2021 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-33720316

RESUMO

CONTEXT.­: ABO mistransfusions are rare and potentially fatal events. Protocols are required by regulatory agencies to minimize this risk to patients, but how these are applied in the context of massive transfusion protocols (MTPs) is not specifically defined. OBJECTIVE.­: To evaluate the approaches used by transfusion services for switching from universally compatible to patient ABO type-specific blood components during massive hemorrhage. DESIGN.­: We added 1 supplemental multiple-choice question to address the study objective to the 2019 College of American Pathologists proficiency test J-survey (J-A 2019). We also reviewed the available literature regarding this topic. RESULTS.­: A total of 881 laboratories responded to the supplemental question. Approximately 80% (704 of 881) reported a policy for ABO-type switching during an MTP. Policies varied considerably between responding laboratories, but most (384 of 704, 55%) required 2 ABO types to match before switching from universal to recipient-specific blood components. Additional safety measures used in a minority of these protocols included reaction strength criteria (103 of 704, 15%), on-call medical director approval (41 0f 704, 5.8%), universal red cell unit number limits (12 of 704, 1.7%), or the presence of a mixed field (3 of 704, 0.4%). CONCLUSIONS.­: This survey reveals that significant heterogeneity exists regarding the available approaches for ABO-type switching during an MTP. Specific expert guidance regarding this issue is very limited, and best practices have not yet been established or rigorously investigated.


Assuntos
Tipagem e Reações Cruzadas Sanguíneas , Transfusão de Sangue , Transfusão de Componentes Sanguíneos , Hemorragia/etiologia , Humanos , Inquéritos e Questionários
2.
Arch Pathol Lab Med ; 143(12): 1539-1544, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31173529

RESUMO

CONTEXT.­: The Kleihauer-Betke (KB) test is validated for estimating the dose of Rh immune globulin needed for Rh-negative pregnant females. However, some clinicians are also ordering the test for Rh-positive women. The degree to which this practice occurs is unknown. OBJECTIVE.­: To evaluate the number of laboratories that perform the KB test on Rh-positive pregnant women, and to establish current ordering practices for this indication. DESIGN.­: We added 9 supplemental questions regarding KB test use for fetomaternal hemorrhage to the 2016 College of American Pathologists proficiency test survey. We also reviewed the available literature regarding the diagnostic utility of the KB test for Rh-positive women. RESULTS.­: A total of 1578 surveys were evaluated and revealed that 52% (824) of respondents perform these tests for Rh-positive women, and more than 50% (440 of 819; 53.7%) of these laboratories report that the results for Rh-positive women are treated as important or very important. CONCLUSIONS.­: The KB test is commonly used for Rh-positive women, and the information obtained from the test is considered as urgent and important. However, the available literature in support of this practice is still nonconclusive.


Assuntos
Hemoglobina Fetal/análise , Transfusão Feto-Materna/diagnóstico , Testes Hematológicos/métodos , Laboratórios/estatística & dados numéricos , Feminino , Humanos , Gravidez , Sistema do Grupo Sanguíneo Rh-Hr , Inquéritos e Questionários
3.
Arch Pathol Lab Med ; 138(9): 1141-9, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25171696

RESUMO

CONTEXT: During the past 25 years, the College of American Pathologists' (CAP) Q-Probes program has been available as a subscription program to teach laboratorians how to improve the quality of clinical laboratory services. OBJECTIVE: To determine the accomplishments of the CAP Q-Probes program. DESIGN: We reviewed Q-Probes participant information, study data and conclusions, author information, and program accomplishments. RESULTS: During this time 117 Q-Probes clinical pathology studies were conducted by 54 authors and coauthors, 42,899 laboratories enrolled from 24 countries, 98 peer-reviewed publications occurred and were cited more than 1600 times, and the studies were featured 59 times in CAP Today. The most frequent studies (19) focused on turnaround times for results or products at specific locations (emergency department, operating room, inpatients, outpatients), specific diseases (acute myocardial infarction, urinary tract), availability for specific events such as morning rounds or surgery, a specific result (positive blood cultures), and a method on how to use data for improvement (stat test outliers). Percentile ranking of study participants with better performance provided benchmarks for each study with attributes statistically defined that influenced improved performance. Other programs, such as an ongoing quality improvement program (Q-Tracks), a laboratory competency assessment program, a pathologist certification program, and an ongoing physician practice evaluation program (Evalumetrics), have been developed from Q-Probes studies. CONCLUSIONS: The CAP's Q-Probes program has made significant contributions to the medical literature and has developed a worldwide reputation for improving the quality of clinical pathology services worldwide.


Assuntos
Laboratórios/história , Patologia Clínica/história , Certificação , História do Século XX , História do Século XXI , Humanos , Laboratórios/normas , Patologia Clínica/normas , Competência Profissional , Garantia da Qualidade dos Cuidados de Saúde/história , Sociedades Médicas , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA